Actinium Pharmaceuticals Stock Price. Everything You Need To Know About The Actinium Pharmaceuticals Stock!
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 49 full-time employees. The company went IPO on 2014-03-26. The firm is focused on developing and commercializing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs. Its clinical programs use its Antibody Warhead Enabling (AWE) technology platform. Its clinical pipeline is led by Antibody Radiation-Conjugates (ARCs). Its lead product candidate, Iomab-B (I-131 apamistamab), is a targeted conditioning agent, which consists of an anti-CD45 monoclonal antibody and the radioisotope Iodine-131 (I-131). Its clinical and preclinical development programs utilize multiple isotopes, including Actinium-225, Iodine-131 and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2 and HER3 for targeted conditioning prior to cell and gene therapies, including bone marrow transplant (BMT) and cancer therapeutics in combination with other therapeutic modalities.
Actinium Pharmaceuticals Stock Price. Everything You Need To Know About The Actinium Pharmaceuticals Stock! performance
- Employees 49
- Company HQ New York City
- Website https://www.actiniumpharma.com/
- ATNM Asset Type Common Stock
- ATNM Market Capitalization 216.9M
- Earnings Per Share -1.83
- Dividends Per Share None
- Dividend Date 2020-08-11
- Quarterly Earnings Growth 0
Are you a retail investor from Malaysia, Thailand, Indonesia, or Vietnam looking to invest in the stock market? Consider Actinium Pharmaceuticals, a promising opportunity in the healthcare sector. Actinium Pharmaceuticals is a US-based biopharmaceutical company focused on developing innovative therapies for cancer treatment. With its cutting-edge technology and robust pipeline, Actinium Pharmaceuticals shows great potential for growth. As a retail investor from Malaysia, Thailand, Indonesia, or Vietnam, you can take advantage of Zorion’s investment platform to access Actinium Pharmaceuticals stock and take informed investment decisions. Utilize our investment insights, recommendations, and educational resources to enhance your investment knowledge and make sound investment choices. Start investing in Actinium Pharmaceuticals today with Zorion and unlock the potential for significant returns.
